Abstract
ObjectiveOvarian cancer (OC) is one of the most aggressive women cancers with increasing incidence and mortality rates worldwide. Long non-coding RNAs (lncRNAs) could as major players in OC process. Although FAM83H antisense RNA1 (FAM83H-AS1) is demonstrated play an important roles in a many cancers, the detailed function and mechanism has not been reported in OC.ResultsWe integrated multiple kinds of bioinformatics approaches and experiments validated method to evaluate functions of FAM83H-AS1 in OC. Some differential expressed lncRNAs were identified between OC and normal control tissues. FAM83H-AS1 was one of most differentially expressed lncRNAs and up-regulated in multiple cancer types. Specially, expression of FAM83H-AS1 was higher in OC and showed difference in diverse stages. High FAM83H-AS1 expression is associated with worse pan-cancer and OC outcomes. FAM83H-AS1-centric network including lncRNA-miRNA, lncRNA-protein and lncRNA-mRNA ceRNA network were constructed to infer the function and mechanism of FAM83H-AS1. There were two methylation sites including cg01399317 and cg20519035 located at FAM83H-AS1. The methylation level of cg01399317 was correlated with gene expression of FAM83H-AS1. The expression level of FAM83H-AS1 was correlated with infiltration level of immune cell including macrophage, neutrphil and dendritic cell in OC patients. Lastly, qRT-PCR showed that the expression of FAM83H-AS1 was higher in OC tissues than normal control tissues.ConclusionCollectively, these results indicated that FAM83H-AS1 may act as an oncogenic driver and it may be a potential therapy target in OC.
Highlights
In the female reproductive system, ovarian cancer (OC) is one of the most malignant tumors [1]
Some dysregulated genes and Long non-coding RNAs (lncRNAs) were identified in OC We identified differential expressed coding genes and lncRNAs between ovarian serous cystadenocarcinoma (OV) tissues and normal control tissues to screen candidate genes. 2419 differential expressed lncRNAs and coding genes were identified based on ttest (P < 0.001) for OV patients (Fig. 1a)
We further focused on dysregulated lncRNAs in OC
Summary
In the female reproductive system, ovarian cancer (OC) is one of the most malignant tumors [1]. As cancer statistics in China and United States suggested that the mortality rate of OC has been rising for the past few years [2, 3]. There will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States [4]. 2.5% of all female malignant tumors and part of deaths for cancer patients due to poor survival which largely driven by late stage diagnoses [5]. Advancing insight about mechanism and treatment of OC has been evolved rapidly in recent year, survival rates have improved only slightly over the past 3 decades. Improving prevention and early detection based on identifying molecular biomarkers are effective ways to enhance survival for OC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
